- Phase 2 pancreatic cancer follow-up extended as atebimetinib patients live longer than projected; updated data (N=55) expected in 1H 2027.
- Phase 3 MAPKeeper 301 enrollment running ahead of schedule, expanding target from 510 to 570 patients with potential acceleration of mid-2028 data.
- Cash, equivalents and marketable securities stood at $166.1M as of Sept 30, 2026, down from $217.0M at end of 2025.
?? Positive AI Sentiment (+4.5 / 10)